RELMADA THERAPEUTICS INC's ticker is RLMD and the CUSIP is 75955J402. A total of 145 filers reported holding RELMADA THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 2.08 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,877 | -97.5% | 4,959 | -97.9% | 0.00% | – |
| Q2 2023 | $586,210 | +1.8% | 238,297 | -6.5% | 0.00% | – |
| Q1 2023 | $575,717 | -31.0% | 254,742 | +6.5% | 0.00% | – |
| Q4 2022 | $834,721 | -90.5% | 239,175 | +0.8% | 0.00% | -100.0% |
| Q3 2022 | $8,785,000 | +93.5% | 237,306 | -0.8% | 0.01% | +66.7% |
| Q2 2022 | $4,541,000 | -29.5% | 239,133 | +0.2% | 0.00% | 0.0% |
| Q1 2022 | $6,439,000 | +2711.8% | 238,573 | +2248.4% | 0.00% | – |
| Q4 2021 | $229,000 | -47.0% | 10,159 | -38.4% | 0.00% | – |
| Q3 2021 | $432,000 | -13.8% | 16,481 | +5.2% | 0.00% | – |
| Q2 2021 | $501,000 | -11.0% | 15,661 | -2.2% | 0.00% | – |
| Q1 2021 | $563,000 | +51.8% | 16,018 | +38.0% | 0.00% | – |
| Q4 2020 | $371,000 | +26.2% | 11,607 | +48.5% | 0.00% | – |
| Q3 2020 | $294,000 | -8.1% | 7,817 | +9.5% | 0.00% | – |
| Q2 2020 | $320,000 | – | 7,136 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 853,206 | $30,041,000 | 3.26% |
| COMMODORE CAPITAL LP | 161,565 | $5,689,000 | 2.27% |
| TANG CAPITAL MANAGEMENT LLC | 200,000 | $7,042,000 | 1.98% |
| PARSONS CAPITAL MANAGEMENT INC/RI | 451,412 | $15,894,000 | 1.30% |
| Avoro Capital Advisors LLC | 1,525,000 | $53,695,000 | 0.93% |
| RTW INVESTMENTS, LP | 1,530,717 | $53,897,000 | 0.84% |
| Pegasus Asset Management, Inc. | 26,958 | $949,000 | 0.48% |
| COWEN AND COMPANY, LLC | 166,942 | $5,878,000 | 0.40% |
| Ikarian Capital, LLC | 290,207 | $10,218,000 | 0.34% |
| Spotlight Asset Group, Inc. | 24,565 | $865,000 | 0.32% |